JAM-B/VE-JAM Antibodies

HAF017). Specific bands were detected for JAM-B/VE-JAM at approximately 43-50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_lightbox"> HAF017). Specific bands were detected for JAM-B/VE-JAM at approximately 43-50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of human placenta tissue and human testis tissue. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human/Mouse JAM-B/VE-JAM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1074) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). Specific bands were detected for JAM-B/VE-JAM at approximately 43-50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />

HAF017). Specific bands were detected for JAM-B/VE-JAM at approximately 40-48 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_lightbox"> HAF017). Specific bands were detected for JAM-B/VE-JAM at approximately 40-48 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />

VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to plasma membrane in endothelial cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox"> VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to plasma membrane in endothelial cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_thumb" />

HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system." class="big_lightbox"> HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system." class="big_thumb" />

1074-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Human JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human/Mouse JAM-B/VE-JAM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1074). The ND₅₀ is typically 0.2-0.8 µg/mL." class="big_lightbox"> 1074-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Human JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human/Mouse JAM-B/VE-JAM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1074). The ND₅₀ is typically 0.2-0.8 µg/mL." class="big_thumb" />

988-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Mouse JAM‑B/VE‑JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse JAM-B/VE-JAM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF988). The ND₅₀ is typically 0.6-3.0 µg/mL." class="big_lightbox"> 988-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Mouse JAM‑B/VE‑JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse JAM-B/VE-JAM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF988). The ND₅₀ is typically 0.6-3.0 µg/mL." alt="Recombinant Mouse JAM‑B/VE‑JAM Fc Chimera (Catalog # 988-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Mouse JAM‑B/VE‑JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse JAM-B/VE-JAM Antigen Affinity-purified Polyclonal Antibody (Catalog # AF988). The ND₅₀ is typically 0.6-3.0 µg/mL." class="big_thumb" />

988-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Mouse JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB988). The ND₅₀ is typically 0.1-0.5 µg/mL." class="big_lightbox"> 988-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Mouse JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB988). The ND₅₀ is typically 0.1-0.5 µg/mL." alt="Recombinant Mouse JAM-B/VE-JAM Fc Chimera (Catalog # 988-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Mouse JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB988). The ND₅₀ is typically 0.1-0.5 µg/mL." class="big_thumb" />

988-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Mouse JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB9881). The ND₅₀ is typically 0.1-0.5 µg/mL." class="big_lightbox"> 988-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Mouse JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB9881). The ND₅₀ is typically 0.1-0.5 µg/mL." alt="Recombinant Mouse JAM-B/VE-JAM Fc Chimera (Catalog # 988-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Mouse JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB9881). The ND₅₀ is typically 0.1-0.5 µg/mL." class="big_thumb" />

F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB003). View our protocol for Staining Membrane-associated Proteins." class="big_lightbox"> F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB003). View our protocol for Staining Membrane-associated Proteins." alt="HEK293 human embryonic kidney cell line transfected with (A) human JAM-B/VE-JAM or (B) irrelevant transfectants and eGFP was stained with Mouse Anti-Human JAM-B/VE-JAM Monoclonal Antibody (Catalog # MAB10744) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB003). View our protocol for Staining Membrane-associated Proteins." class="big_thumb" />

1074-VJ), immobilized onto a microplate supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by Calcein AM. Adhesion elicited by Recombinant Human JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human JAM-B/VE-JAM Monoclonal Antibody (Catalog # MAB10744). The ND₅₀ is typically 35-210 ng/mL." class="big_lightbox"> 1074-VJ), immobilized onto a microplate supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by Calcein AM. Adhesion elicited by Recombinant Human JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human JAM-B/VE-JAM Monoclonal Antibody (Catalog # MAB10744). The ND₅₀ is typically 35-210 ng/mL." class="big_thumb" />

1074-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Human JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB10741). The ND₅₀ is typically 0.6-3.0 µg/mL." class="big_lightbox"> 1074-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Human JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB10741). The ND₅₀ is typically 0.6-3.0 µg/mL." alt="Recombinant Human JAM-B/VE-JAM Fc Chimera (Catalog # 1074-VJ), immobilized onto a microplate previously coated with Goat Anti-Human IgG Fc (Catalog # G-102-C), supports the adhesion of the J45.01 human acute lymphoblastic leukemia T lymphocyte cell line in a dose-dependent manner (orange line), as measured by endogenous cellular lysosomal acid phosphatase activity. Adhesion elicited by Recombinant Human JAM-B/VE-JAM Fc Chimera (0.2 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human JAM-B/ VE-JAM Monoclonal Antibody (Catalog # MAB10741). The ND₅₀ is typically 0.6-3.0 µg/mL." class="big_thumb" />

F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB0041). View our protocol for Staining Membrane-associated Proteins." class="big_lightbox"> F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB0041). View our protocol for Staining Membrane-associated Proteins." alt="HEK293 human embryonic kidney cell line transfected with either (A) human JAM-B or (B) irrelevant transfectants and eGFP was stained with Mouse Anti-Human JAM-B Monoclonal Antibody (Catalog # MAB10742) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB0041). View our protocol for Staining Membrane-associated Proteins." class="big_thumb" />

F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB003). View our protocol for Staining Membrane-associated Proteins." class="big_lightbox"> F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB003). View our protocol for Staining Membrane-associated Proteins." alt="HEK293 human embryonic kidney cell line transfected with (A) human JAM-B/VE-JAM or (B) irrelevant transfectants and eGFP was stained with Mouse Anti-Human JAM-B/VE-JAM Monoclonal Antibody (Catalog # MAB10743) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based on control antibody staining (Catalog # MAB003). View our protocol for Staining Membrane-associated Proteins." class="big_thumb" />